Nasal drug delivery: New developments and strategies

Drug Discovery Today

Volumn 7, Issue 23, 2002, Pages 1184-1189

  Illum, Lisbeth ^a  

^a IDentity   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; APOMORPHINE; BUSERELIN; BUTORPHANOL; CALCITONIN; CHOLECYSTOKININ; CORTICOTROPIN; ERGOTAMINE; ESTRADIOL; FENTANYL DERIVATIVE; INFLUENZA VACCINE; INSULIN; LEUPRORELIN; MELATONIN; MIDAZOLAM; MORPHINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE; SUMATRIPTAN; ZOLMITRIPTAN;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; HUMAN; NOSE ALLERGY; NOSE CAVITY; NOSE CONGESTION; REVIEW; SIDE EFFECT; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NASAL MUCOSA;

EID: 0036896831     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02529-1     Document Type: Review

References (34)

1. Illum, L. Nasal drug delivery - Possibilities, problems and solutions. J. Control. Release (in press).
2. Illum L., et al. Chitosan as a novel nasal system for vaccines. Adv. Drug. Deliv. Rev. 51:2001;81-96.
3. Davis S. Nasal vaccines. Adv. Drug. Deliv. Rev. 51:2001;21-42.
4. McMartin C., et al. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76:1987;535-540.
5. Madara J.L., Dharmsathaphrn K. Occluding junction structure function relationship in a cultured epithelial monolayer. J. Cell Biol. 101:1985;2124-2133.
6. Inagaki M., et al. Macromolecular permeability of the tight junction of the human nasal mucosa. Rhinology. 23:1985;213-221.
7. Soane R.J., et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 178:1999;55-65.
8. Illum L. Bioadhesive formulations for nasal peptide delivery. Mathiowitz E., et al. Drug Delivery Issues in Fundamentals, Novel Approaches and Development. 1998;507-539 Marcel Dekker, New York.
9. Moore K.H., et al. Safety, tolerability and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia. 17:1997;541-550.
10. Illum L. Nasal delivery. The use of animal models to predict performance in man. J. Drug Target. 3:1996;427-442.
11. Merkus F.W., et al. Interspecies difference in the nasal absorption of insulin. Pharm. Res. 8:1991;1343.
12. Illum L., et al. Chitosan as a novel nasal delivery system for peptides drugs. Pharm. Res. 11:1994;1186-1189.
13. Davis, S.S. and Illum, L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet. (in press).
14. Illum, L. (2002) Nasal delivery of insulin. Proceedings from Diabetes Management - Management Forum, 28 February - 1 March 2002, London, UK.
15. Illum L., et al. Novel chitosan based delivery systems for nasal administration of a LHRH-analogue. STP Pharma. 10:2000;89-94.
16. Illum L., et al. Intranasal delivery of morphine. J. Pharmacol. Exp. Ther. 301:2002;1-10.
17. Wilcock, A. et al. Nasal morphine for the treatment of breakthrough pain in cancer patients. J. Pain Symptom Manage. (in press).
18. Artursson P., et al. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:1994;1358-1361.
19. Dodane V., et al. Effect of chitosan on the epithelial permeability and structure. Int. J. Pharm. 182:1999;21-32.
20. Schipper N.G.M., et al. Chitosan as absorption enhancers for poorly absorbed drugs 2: Mechanism of absorption enhancement. Pharm. Res. 14:1997;923-929.
21. Natsume H., et al. Screening of cationic compounds as an absorption enhancer for nasal drug delivery. Int. J. Pharm. 5:1999;1-12.
22. Ohtake K., et al. Enhancing mechanism of poly-l-arginine in nasal absorption of FITC-dextran. Prooceed. Int. Symp. Control. Rel. Bioact. Mater. 25:1998;687-688.
23. Wang J., et al. Aminated gelatine as a nasal absorption enhancer for peptide drugs: evaluation of absorption enhancing effect and nasal mucosa perturbation in rats. J. Pharm. Pharmacol. 54:2002;181-188.
24. Merkus F.W.H.M., et al. Cyclodextrins in nasal drug delivery. Adv. Drug Deliv. Rev. 36:1999;41-57.
25. Marttin E., et al. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target. 6:1998;17-36.
26. Hilsted J., et al. Intranasal insulin therapy: the clinical realities. Diabetologia. 38:1995;680-684.
27. Drejer K., et al. Intranasal administration of insulin with phospholipid as absorption enhancer: Pharmacokinetics in normal subjects. Diabetic Med. 9:1992;335-340.
28. Genetic Engineering News (2002) 22, 22 and 94.
29. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11:2000;1-18.
30. Chow H., et al. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J. Pharm. Sci. 88:1999;754-758.
31. Dahlin M., et al. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm. Res. 17:2000;737-742.
32. Dahlin M., et al. Levels of dopamine in blood and brain following nasal administration to rats. Eur. J. Pharm. Sci. 14:2001;75-80.
33. Fehm H.L., et al. Manipulating neuropeptidergic pathways in humans: A novel approach to neuropharmacology. Eur. J. Pharmacol. 405:2000;43-54.
34. Sankar C., et al. Chitosan based pentazocine microspheres for intranasal systemic delivery: development and biopharmaceutical evaluation. Pharmazie. 56:2001;223-226.